Window of Opportunity in Preserving Laryngeal Function Trial

This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.

Trial Details

NCT ID
NCT07423078
Phase
PHASE2
Sponsor
Matthew Spector
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Toripalimab
  • Carboplatin
  • Cisplatin
  • Paclitaxel
  • Radiation Therapy
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Pathologically confirmed and previously untreated squamous cell carcinoma of the larynx or hypopharynx
  • AJCC 8th Edition Stage III - IV disease (T1-T2/N1-N3, T3-T4/N0-N3)
  • Disease (primary \& nodal) must be potentially surgically resectable and curable with conventional surgery and CRT
  • ECOG PS 0 - 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →